BG
TYRA icon

Bellevue Group’s Tyra Biosciences TYRA Stock Holding History

Bellevue Group’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,143
Closed -$82.6K – 192
2025
Q4 		$82.6K Buy
+3,143
New +$57.7K ﹤0.01% 168

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bellevue Group's TYRA Position: Q1 2026 in Review

Bellevue Group sold out of Tyra Biosciences (TYRA) in Q1 2026, closing a stake of 3,143 shares — an estimated $82.6K sold.

Bellevue Group first reported a position in TYRA in Q4 2025 and held it in 1 quarter. The position peaked at $82.6K in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Bellevue Group reported no remaining Tyra Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 3,143 Tyra Biosciences shares in Q1 2026, an estimated $82.6K.
  • Bellevue Group first reported a position in Tyra Biosciences in Q4 2025 and held it in 1 quarter.
  • Bellevue Group's Tyra Biosciences position peaked at $82.6K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.